Satellos Bioscience Inc. (MSLE) Stock Ticker
Market factors today
Unlock the full MSLE picture
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
MSLE stock facts
| Ticker symbol | MSLE |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $11.2M |
| CEO | Francis Gleeson |
| Employees | 18 |
| Headquarters | Toronto, ON, CA |
| IPO date | 2012-08-03 |
| Website | satellos.com |
What you can see for MSLE on Tickr
Live MSLE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MSLE report.
Rankings
FAQ
What is the ticker symbol for Satellos Bioscience Inc.?
The ticker symbol for Satellos Bioscience Inc. is MSLE, listed on the NASDAQ.
What is MSLE?
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy…